// App-Quantinova.ai

3021 : Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Researchers

Presenter

  • Kami J. Maddocks

Principal Investigators

  • Johannes Duell

  • Eva Gonzlez-Barca

  • Wojciech Jurczak

  • Anna Marina Liberati

  • Sven de Vos

  • Zsolt Nagy

  • Ale Obr

  • Gianluca Gaidano

  • Pau Abrisqueta

  • Marc Andr

  • Martin Dreyling

  • Tobias F Menne

  • Maren Dirnberger-Hertweck

  • Johannes Weirather

  • Sumeet Ambarkhane

  • Gilles Salles

Medical Centers

  • Department of Internal Medicine,Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center,Columbus, OH,United States

  • Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Wurzburg, Germany

  • Department of Hematology, Institut Catalá d’Oncologia (ICO), Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, Barcelona, Spain

  • Clinical Oncology Clinic, Maria Sklodowska-Curie National Research Institute of Oncology, Cracov, Poland

  • Università degli Studi di Perugia,Azienda Ospedaliera Santa Maria di Terni,Terni,Italy

  • Department of Medicine, Ronald Reagan UCLA Medical Center, Santa Monica, CA

  • First Department of Internal Medicine, Semmelweis University, Budapest, Hungary

  • Department of Hemato-Oncology, Palacky University Olomouc and the University Hospital Olomouc, Olomouc, Czech Republic

  • Division of Hematology, Department of Clinical and Experimental Medicine, Universita del Piemonte Orientale Amedeo Avogadro, Novara, Italy

  • Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona, Spain

  • Department of Hematology, Universite catholique de Louvain, CHU UCL Namur, Yvoir, Belgium

  • City Hospital, Munich, Germany

  • Department of Biochemistry, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

  • MorphoSys AG, Planegg, Germany

  • Hématologie, Hospices Civils de Lyon and Université de Lyon, Lyon, France

Locations

  • United States

  • Germany

  • Spain

  • Poland

  • Italy

  • Hungary

  • Czech Republic

  • Belgium

  • United Kingdom

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • B cell lymphomas

  • Lymphomas

Biomarkers

  • Cluster of Differentiation 19

  • Cluster of differentiation 95

Drug/Treatment

  • Lenalidomide

  • Tafasitamab

  • Mofezolac

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Multinational

Phase

  • II

Study Id's

  • NCT02399085

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved